For example, the glutaminase inhibitor telaglenastat (CB-839) in Phase II trials for KEAP1/NFE2L2-mutant NSCLC (NCT04265534, NCT03872427).91 The gene discussed is KEAP1; the disease is non-small cell lung carcinoma.